Study on Pembrolizumab and Sunitinib Malate for Treating Thymic Cancer That Has Spread or Cannot Be Removed by Surgery

Inclusion Criteria

• Be willing and able to provide written consent to participate in the study.
• Have a confirmed diagnosis of advanced thymic carcinoma that cannot be cured with surgery or other treatments.
• Have experienced cancer progression after at least one previous treatment with platinum-based chemotherapy.
• Have measurable cancer based on specific medical criteria.
• Be able to provide a recent tumor tissue sample for analysis.
• Be willing to provide a blood sample at the start of the study and during specific treatment cycles.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have a life expectancy of more than 3 months.
• Be able to swallow and retain oral medication.
• Have controlled blood pressure, with or without medication.
• Have normal heart function as determined by specific tests.
• Have adequate blood cell counts and organ function as indicated by specific blood tests.
• Women of childbearing potential must have a negative pregnancy test before starting treatment and agree to use effective contraception during the study and for 120 days after the last dose.
• Men must agree to use effective contraception during the study and for 120 days after the last dose.

Exclusion Criteria

• Currently participating in another study or have recently received an investigational treatment.
• Have previously received pembrolizumab or sunitinib for cancer treatment.
• Have an immune system deficiency or are taking medications that suppress the immune system.
• Have a history of active tuberculosis.
• Have allergies to pembrolizumab or sunitinib.
• Have had recent chemotherapy, targeted therapy, or radiation therapy and have not recovered from side effects.
• Have another active cancer that requires treatment, except for certain skin cancers or in situ cervical cancer.
• Have active cancer spread to the brain or spinal cord, unless stable and not requiring steroids.
• Have an active autoimmune disease requiring treatment in the past 2 years.
• Have an active infection requiring treatment.
• Have any condition that might interfere with the study or is not in the best interest of the participant.
• Have psychiatric or substance abuse disorders that would interfere with study participation.
• Are pregnant or breastfeeding, or planning to conceive or father a child during the study and for 120 days after.
• Have a history of HIV or active hepatitis B or C.
• Have received a live vaccine within 30 days before starting the study.
• Have significant protein in the urine or serious non-healing wounds.
• Have had recent serious heart or blood vessel problems.
• Are taking medications that strongly affect certain liver enzymes.